Skip to main content
CELC $56.91 +2.36%
CELC logo
CELC · Celcuity Inc.
Track CELC — free
$56.91 +1.31 (+2.36%) Play latest call Q3 2026 earnings call transcript
Market Cap
$2.73B
Shares
49.13M
Volume · Nov 19 352.95K Avg daily vol (3M) 1.23M
All webcasts

Conference · 2026-11-18

Celcuity Inc. (CELC) November 18, 2026 Conference Transcript

Concluded Nov 18, 2026 Audio replay
Nov 18, 2026 27:08 51 turns
Period
2026-11-18
Runtime
27:08
Sources
2 artifacts

Transcript & audio

27:08 Audio
Analyst

And I'm one of the biotech analysts at Jefferies. I'd like to welcome the CEO of Cellcuity, Brian Sullivan. We're going to do fireside chat format, so maybe for those who are new to the story, Brian, if you can give a brief intro to Cellcuity.

Sure. Well, Cellcuity is focused on developing therapeutics that address the PI3K-AKT mTOR pathway. This pathway, which we refer to as PAM, is probably one of the most important oncogenic targets in cancerous solid tumors. It's also one of the hardest pathways to address because it includes multiple components that cross-activate each other if only one component is inhibited and the others aren't. We have advanced to approval. Our first approved drug is RevTropik for patients who are in the second-line setting for HR-positive, HER2-negative breast cancer. That's based on data we generated that showed really unprecedented results, the most favorable hazard ratio reported in any breast cancer study prior. We have an SNDA that is getting reviewed now with the Bidoof mid-8 second quarter next year, and that's for patients in the PIC3CA mutant setting. Data, again, very, very favorable and twice as effective as the comparator. And it was the first study to compare two inhibitors of this pathway head-to-head. We have two phase three studies in process in the first-line setting. These are women, again, HR positive, HER2 negative, represent roughly 90,000 patients. And so when you take into account the addressable market in the second-line setting, we estimated it's roughly $9 billion, so a very significant financial opportunity. And then in the first-line setting, it's just call it north of $20 billion, So a very significant patient population, extended duration of treatment. In the first line, endocrine-sensitive population, we reported roughly 48 months, median PFS, which compares favorably to the standard of care, median PFS of roughly 25 months. So we believe that study, as well as the second study in treatment-naive patients who are endocrine-resistant, both have a, you can assign a high probability of success to it, at least we do. And then we're working in the prostate cancer area as well. Similar underlying biological hypothesis. Hormonally-driven tumor where you have, in this case, the androgen receptor pathway interacting, cooperating with the PAM pathway to promote hyperproliferation.

Analyst

Got it. Yeah, it's a great intro. Covered a lot there. Let's dive into the launch. In your third quarter earnings update, you mentioned you reached 78% of your top 36 accounts within the first month. What separates the accounts already ordering from those still working through the process?

Well, I would focus on the 78 percent because typically to get these strategic accounts, which represent or rather treat roughly 50 percent of all the patients who are treated in the breast cancer setting. And these accounts include, for instance, this representation or include, say, U.S. Oncology, One Oncology, Dana-Farber, City of Hope, very large accounts that essentially have a top-down process for allowing their physicians to prescribe the medicine or have the option to prescribe the medicine. There are a lot of gates that are required to address, and the best evidence of getting through all those gates, which in most cases takes months and can take half a year, but the evidence that we have, in effect, gotten that gate lifted at those accounts was being able to have physicians prescribe the medicine. And so the remaining accounts... Or just operating, they may have a more complex process, a process that's not as aggressive, and we don't see any issues at those accounts. It's just more of an administrative lag than any other factor.

Analyst

Okay, that makes sense. And how broad is adoption beyond physicians who already know gadolizib through Victoria 1 or the EAP, particularly in the community setting?

So we didn't have a huge footprint in the U.S. I mean, one of the disappointing aspects of developing drugs in the U.S. is that you tend to have relatively low participation by U.S. sites. Much, much higher percentage of your patients come from either Europe or Asia or Latin America. So we had a base of doctors, but I would say the great, great majority of the physicians who are prescribing medicine today are ones who didn't have experience in our trials. The EAP population, we've characterized it as a handful because we were really only giving an opportunity to utilize that program for about five weeks. It got approved in the middle of August. We had anticipated having availability of drug available by the end of the quarter. And so for many of these sites, the time to get an EAP approved as a protocol, it's considered a clinical trial, is longer than that five-week period. So there was not a lot of incentive to utilize the program by most sites. Some did, because they had a short approval process to bring on that study. So again, the demand that we'll report for the fourth quarter. We'll reflect almost all demand that was generated during the quarter.

Analyst

Got it. Okay. Okay. And it's early, but are you getting some insight into use differences in second line versus third line, and where do you predict it's ultimately going to settle in the treatment sequence?

So our drug is distributed on a buy-in bill basis. Which means that distributors place the order, accounts will have a distributor that they rely on, a McKesson or Sancora, for instance. That order will come into our 3PL, our distribution hub, and there's no corresponding doctor or patient data. So essentially, all we get is a ship to address and an account. So we're not able to really get much insight into the patient profile or even the doctor. What information we do get, we get from our... Oncology sales specialists who hear anecdotally as they follow up with doctors after they heard that they've prescribed medicine for a patient. And so what we're hearing is that most of the prescriptions, at least as reported by these sales specialists, are second line versus later line. And we think that probably largely reflects the simple fact that there are more second line patients than later line patients. And if a patient presents, and again, we don't have a backlog of patients that have received Reptripic before. As patients present with progressive disease, they've either progressed on the first-line or second-line therapy. Reptripic represents a great option for those patients, and so they're, depending on the patient, going to select a therapy. And so we don't think it's a reflection, whatever the treatment pattern is today, a reflection of a preference for second versus third line, for instance, in thinking about the sequence.

Analyst

Got it. That makes sense. And so you get the SHIP2 address. What are you seeing there as far as adherence and logistical issues go?

Well, it's actually very straightforward. So if we get an order by 3 p.m., we can ship it, and the site will receive it the next day. So what that means is we don't have a channel that needs to be filled to support distribution. We don't have specialty pharmacies that ultimately are a distribution hub for us. And so we're basically fulfilling demand as patients are prescribed the medicine. Because it's just in time, essentially, it really facilitates the ability of the account to schedule. And because the infusion period is only 30 minutes, it's very easy. This is feedback we've received. Very easy for them to find a slot for those patients pretty much whenever they... They need to or want to have that patient come in for their infusion.

Analyst

Got it. And as far as the weekly visits go, it seems like that's pretty straightforward. But can you get any perspective into whether patients are coming back in for more treatments?

Well, it's only on days 1, 8, 15, so basically three infusions over a two-week period, and then the patients are off for two weeks. We haven't gotten any feedback, so just compliance. And we didn't see that at very, very limited amounts in the second-line study, and that was, you know, mostly primarily a factor in certain countries that enrolled, just the country was a lower-income country that just had more barriers for patients to participate in studies.

Analyst

And what are you hearing on tolerability? I guess, how are the first commercial patients tolerating the drug, particularly during cycle one, and how consistently are sites using the steroid mouth rinse?

Well, we had a lot of experience because we've treated over 1,000 patients with Reptripic, and in study 1, which treated patients who lacked PIC-3C mutations, and study 2 of our Victoria 1 study, patients with PIC-3C mutations, we found very consistent results, except that in study 2, the results were more favorable. And we think that reflects the fact that physicians had more experience with the drug because that population took longer to enroll, and they had a longer period of time to essentially learn how to manage the medicine. But the feedback, early feedback, and this is something we've paid a lot of attention to, we've required all of our sales specialists to follow up after the first week of infusion and second week of infusion, see what they're hearing, get feedback from whomever they can get in touch with about the patient's experience, and no surprises. And in fact, it's been very, very encouraging.

Analyst

Got it. And are you hearing anything on dose holds or reductions having any meaningful effect on vials used per cycle, or is it still too early to assess that?

It's too early, and that's not the type of thing that we're going to get detail on, really. I mean, again, information like that would be primarily anecdotal. It would be hard to I'm going to trend that out.

Analyst

Got it. And it seems like you're planning on doing a flash earnings update in fourth quarter results, sales update, potentially in mid-January. What do you want to do in that early update, and which metrics will best distinguish underlying patient demand from partial cycle orders?

So we're somewhat limited, not somewhat, very limited in the data that we have available to report. I think, you know, And people are used to seeing more granular data from orally administered drugs that are distributed through specialty pharmacies. We just don't get that data. So we won't be able to provide, you know, breadth, i.e., number of physicians prescribing or depth, how many patients per physician data. We'd love to get that. Now, we will be able to get that data retrospectively from a data scrape that will take us about six months to access or six weeks to access. So we won't have real-time data. It will only include about 40 percent, and we're not sure it will be ready for primetime to present publicly just because of the way the data is captured. So we'll be limited, and we'll be evaluating metrics that we think will be interpretable. They'll provide a reliable indication of what's going on, and that first release will. We'll provide what we think is appropriate to give on an ongoing basis.

Analyst

Got it. But the main thing will be the sales and number of vials. And then for the fourth quarter earnings, which you'll probably have in February, you'll have more details on that.

Potentially, right.

Analyst

Okay. And given that sites can order weekly vials rather than a full cycle up front, how should investors translate vials shipped into new starts versus continuing patients and also treatment duration? It's very hard to tease out just looking at the numbers.

You can't distinguish. What is driving one order versus another order? Now, what you can do, and internally we have a lot of metrics that will allow us to look at momentum at an account. We'll also be pushing up those numbers against a model we've created for their accounts that defines their potential. We know how many patients are treated at a particular facility based on the physicians practicing there. So we can estimate. What the ideal or potential is at an account. Now, it may not be reliable because you may have a mix of early breast cancer patients mixed in with late stage. The numbers aren't necessarily precise, but it gives you a relative metric. And so from a management standpoint, it allows us and gives the reps the information needed to say, wow, these numbers look good, but relative to the potential, they're not as good as they should be relative to how other sites are doing. Let's figure out why. And that's where we will have to essentially rely on these relative metrics that, you know, for management purposes. But they're not the type of metrics that are necessarily reportable.

Analyst

Okay. Yeah, sort of like the momentum information that you're seeing, you probably wouldn't share that with the street on a regular basis. Would you share that for your fourth quarter earnings? Unlikely. Unlikely.

No. I mean, just because it's not necessarily interpretable. I mean, when you're at the early stage in particular, there's so many variables. Again, we don't want to report data where if we presented it to 10 people, it'll result in 10 different interpretations. That's not good data, right? You want data that's clear and provides or answers a direct question.

Analyst

And maybe talk about the temporary J-code, how much adoption is currently delayed or impacted by that.

Again, it's hard to put a number to that, but there's definitely a certain cohort of accounts that require J-code prior to allowing the site and physicians to order it. There are a lot that don't, and our reps are cataloging. You know, those accounts, and, you know, the profile of many of them are, you would kind of fall into the category of not-for-profit community hospitals, where financially they may not be as robust, and, you know, they will tell you in verbatim kind of what you hear is, we just have been burned in the past, and we just made this policy. So we'll just have to wait for those accounts until April, and that's just inevitable in any launch with a Part B drug. That's not something we can control or are really specific to what we can control. We can, though, ameliorate that to the extent that it is a concern for some accounts that might be reluctant. We're offering extended payment terms, which essentially addresses this mismatch between them paying for the drug and when they might get reimbursed for it, because that is a concern if their cash flow negative when they're purchasing, after they purchase the drug.

Analyst

Makes sense. And how should investors just think about this pre-J code versus post-J code?

Well, I think once we have the J code, which will happen, we'll get the J code January 1st. It'll become active April 1st. I think certainly there'll be a bit of a tailwind in the second quarter, because to the extent that we've had a restriction on access to some of these They will be able to begin ordering.

Analyst

Yeah, makes sense. And your approximate 20% gross-to-net assumption, that includes 340B and patient support programs. How do you think these components are going to influence or change the 20% gross-to-net assumption as the channel mix evolves and becomes clearer?

Well, we made an assumption about the channel mix that we think was reflective of kind of a steady-state distribution. Certainly, there's potential for volatility quarter to quarter just based on the varying shifts in the proportion of the 340B versus maybe community. So we won't be surprised if we see that number shift around. We're not projecting it right now. I'm just indicating that ultimately that the number will sort itself out, we believe, most likely to be that 80 percent level. But it's that number is primarily driven by 340B. The other numbers that are associated with that that are more variable, we are able to get an early trend on that is independent, for instance, of mix. It's patient-associated, free drug, for instance. And, you know, we're seeing a trend that's consistent with our assumptions.

Analyst

Got it. Makes sense. And let's shift gears to your filing getting accepted. You've got a PDUFA date scheduled for June 25th, 2027. Ahead of approval, what are the key remaining uncertainties around the label and where the label could differentiate from the wild type?

Sure. Well, this study will, or rather, this SNDA is focused on patients with a mutation. The triplet data was clear, you know, 2x winner relative to the control apolipsib plus fulvestrin. It has a ratio of 0.5. What makes a review more complicated for the agency is nothing to do with the triplet. It really is a function of the doublet that we included as a reference, not something, an arm that was statistically powered to detect a difference between the doublet and alpalypsid. And as a result, the agency typically is very cautious when they're considering approving a drug that doesn't have alpha-assigned primary analysis. And so I would just say from a practical standpoint, we felt it was worth seeking an indication for the doublet to have a conversation and have a discussion with the agency. We need to put that in our SMDA in order to engage. But at the same time, we're also practical and understand the obstacles that the agency may. Be dealing with it as they review that. So we'll see. But most importantly, we don't think it creates a barrier for commercialization. Most drugs get launched with a single regimen, single indication. We have approval for both in the wild-type setting. We think it's reasonably like, I can't project, but certainly, given the data, it wouldn't be unreasonable to expect that both of those regimens would get listed in the guidelines and CCN. But TBD, we're still waiting to get our publication. Our journal article published. But so from a commercialization standpoint, we don't think that's going to create a barrier at all to achieving the penetration targets that we're setting.

Analyst

Okay. So either way, whether you get that doublet included or not, it's not going to have too much of an impact on commercial. And should we expect adoption to ram faster in the mutant setting than in the wild type setting, given existing physician awareness and commercial infrastructure?

So most of the wickets that you need to get through, most of the gates you need lifted to get access to the patients, will have already been addressed with the wild type. But you'll still need to get incorporated, have a review by the P&T committee because it's a new indication, you know, review. You don't need to get on the formulary again, but you want to be incorporated into their pathways. And so there's a time element associated with that. But certainly between now and then or since we reported our data, we've been communicating, our market access team has been communicating with these strategic accounts with the payers to facilitate that review and hopefully result in what we've seen so far, which is a rapid turnaround time of that decision.

Analyst

Yeah, makes sense. And you mentioned the publication. Could that support an NCCN recommendation before FDA approval and have payers indicated that a compendial listing would be sufficient for reimbursement?

The journal publication we expect to come out this quarter will submit at that time. We have an approval, so it's possible for NCCN to include us in their guidelines prior to approval, but I can't predict that. They have a schedule, and they may just decide to wait for the approval and the label. I can't really project with any confidence either way. But if we have a 2A or greater recommendation, so a 1 or 2A recommendation, most policies, health insurance policies for patients would reimburse on that basis.

Analyst

Got it. Makes sense. And the mutant study used alpalisib as a control, while much of the current practice has moved toward capivacertib. How do you expect Riftorpic to compete against capivacertib in actual clinical practice?

I think the data has been pretty consistent. They've each had a couple studies done, and have each shown that the results that they get, they've reported relative to full vestment, they use the same control, or about the same, roughly 0.5 hazard ratio. So I think intuitively physicians recognize that Alpalipsa served as a very reliable proxy for Kapovacitrib, and so they can be comfortable, given the delta between what we reported, basically two times a PFS hazard ratio of 0.5, that that will translate to a meaningful benefit relative to what the patients would receive with Kapovacitrib.

Analyst

Got it. Makes sense. And as mutant-selective PI3K inhibitors such as Real Age Drug or Little Age Drug Advance, where do you see Reptorfic fitting in the long-term treatment sequence?

I think we'll be first. I think the data is very clear. The data we showed in the clinical trial, the data we've reported non-clinically that kind of is able to provide insight into the importance of the mechanism has shown that the benefit of inhibiting the pathway comprehensively by inhibiting all four class I isoforms of PI through K as well as mTORC1 and 2 induces a much more potent effect, 300-fold more potent in vitro than, let's say, alpalypsid. And these other drugs don't demonstrate, on a biochemical basis, differentiated potential, rather, potency or efficacy or maximal effect relative to alpalypsid. So mechanistically, it's hard for me to think that. And those drugs would induce a different effect than what we've just compared ourselves to. And if that is the case, which I think is a reasonable conclusion, then I think a reftropic regimen will be the preferred regimen.

Analyst

And with the PAM inhibition, would that still make sense if it was used after one of those drugs?

Potentially. I mean, we don't have data on that, but certainly if you're inhibiting the pathway comprehensively, you have a bunch of the targets that haven't been inhibited, and it's reasonable. And it's speculative on my part, but it certainly wouldn't be an unreasonable assumption to make.

Analyst

Got it. Okay. And maybe talk about XUS strategy and what work needs to be done prior to filing the MAA late 26 or early 27.

So, you know, our strategy is twofold. One is to make sure the regulatory process proceeds, but it's made complicated by the most favored nation pricing rule that's out there, Which people aren't familiar with would require us to sell to U.S. government. Buyers, payers, the lowest price that's made available outside the United States for major OECD countries, which means if you sell the drug today at a price that's consistent with what Germany, for instance, is paying or the U.K., then you could have a potential 20% to 30% reduction in the available served market in the U.S., so a very significant impact. So you have to factor that in, and it also suggests you have to think through exactly and more clearly, or rather more deliberately, the model that you're selecting to distribute XUS. If you license the drug... And don't control, and typically they don't in those agreements, the pricing, you're allowing a third party to potentially have a huge negative impact on your U.S. market, which says, okay, you potentially either need to do it yourself, probably in a limited number of countries, or through a distributor model, and then you also need to consider the downside if you don't win your negotiation. Let's say against the public bears, you don't want to be caught and never, never land. And so you may want to consider, for instance, just focusing on a population that has private insurance. So it's a much more complex decision and thought process than was the case 18 months ago. Right. And so we're going to be very deliberate about that. We're doing a deep analysis, deep study on the... Different approaches that are available to us, and we will proceed accordingly.

Analyst

Got it. And almost out of time, so let's run through a couple quick ones for the sub-Q formulation, maybe talk about just where you're at there and whether we could get updates on that in 2027.

So we're on track. I mean, it's essentially an engineering project at this point, and the goal is to have that available, approved, coincident. Roughly, with the potential approval of the indication in endocrine-sensitive first-line patients. And so I think probably the data that we will provide will be associated with an announcement that we're proceeding to a first-in-human study.

Analyst

Got it. And for the OS data from the wild-type study, we're expecting that first half of next year. I'm wondering if you can say if it could be earlier in the year, and then what are your expectations for what you could show?

Well, two things. In the breast cancer market, approvals have been based on PFS as an endpoint. OS hasn't been a required endpoint. And as a result, sponsors like Cellcuity, for the most part, power their studies to detect a PFS difference, not an OS difference. And since the OS hazard ratio is typically less significant, it's less favorable, you need a larger population. So most studies just simply aren't powered to detect what could be a survival advantage. And that's why, if you were to look at second-line indications in breast cancer, in aceropositive breast cancer, none have a positive or statistically significant OS data. And so that's just level setting the nature of the challenge of having a positive OS readout. The second is that in the wild type, we allow patients to cross over. So we're competing against ourselves. Essentially, 60% of our patients ended up crossing over from filvestrant to either the triplet or the doublet, which is a long way of saying we showed a favorable trend in the interim setting. Wouldn't be a surprise to us if we showed a favorable trend in the final analysis. But, you know, we're measured in our optimism, I guess, and just from, you know, the practical considerations I mentioned.

Analyst

Makes sense. And so we're out of time, so maybe in closing, if you want to highlight key catalysts investors should be focused on.

Well, I'm certainly getting approval, hopefully, getting to the PDUFMA date. You know, we'll have ongoing announcements of our data. We'll probably have some additional updates in the prostate study with, you know, additional patients enrolled in a 240 dose. And then ongoing reporting of our commercialization progress. I think that's probably the catalyst people will be most focused on.

Analyst

Brian, thanks so much for joining us today.

Analyst Q&A · 1 question
Full-screen source Call document